Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing, Jiangsu, China.
Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing, Jiangsu, China.
Int J Biochem Cell Biol. 2018 May;98:43-53. doi: 10.1016/j.biocel.2018.02.015. Epub 2018 Mar 21.
Ischemia/reperfusion (I/R) is a critical risk factor for acute kidney injury (AKI). Recent studies provided evidence that tubular epithelial cells (TEC)-associated inflammation aggravates kidney injury and impairs tissue repair after I/R injury. Here we demonstrated that the Nod-like receptor protein 3 (NLRP3) inflammasome is activated by mitochondrial reactive oxygen species (mROS) during I/R injury via direct interactions between the inflammasome and thioredoxin-interacting protein (TXNIP). Firstly, we found that NLRP3 inflammasome activation was induced by I/R injury, peaking at day 3 after reperfusion. Consistent with this observation, NLRP3 deletion significantly attenuated I/R-induced kidney damage and markers of inflammasome activation. Then, we observed mitochondrial dysfunction, characterized by ultrastructural changes and cytochrome C (Cyt c) redistribution. Mitochondria-targeted antioxidant MitoTEMPO prevented mROS overproduction and the decline in mitochondrial membrane potential (MMP) in vitro. MitoTEMPO treatment also inhibited NLRP3 inflammasome activation and co-localization of NLRP3 and TXNIP after simulated ischemia/reperfusion (SI/R) injury. Finally, we transfected HK-2 cells with TXNIP siRNA to explore the role of TXNIP in mROS-induced NLRP3 inflammasome activation. We found that TXNIP siRNA significantly inhibited NLRP3 inflammasome activation. These results demonstrate that NLRP3 inflammasome is activated through the mROS-TXNIP-NLRP3 pathway and provide a potential therapeutic target in ischemic AKI.
缺血/再灌注(I/R)是急性肾损伤(AKI)的一个关键危险因素。最近的研究提供了证据,表明肾小管上皮细胞(TEC)相关炎症会加重 I/R 损伤后的肾损伤,并损害组织修复。在这里,我们证明,Nod 样受体蛋白 3(NLRP3)炎性小体在 I/R 损伤过程中通过炎性小体与硫氧还蛋白相互作用蛋白(TXNIP)之间的直接相互作用被线粒体活性氧(mROS)激活。首先,我们发现 NLRP3 炎性小体激活是由 I/R 损伤诱导的,在再灌注后第 3 天达到峰值。与这一观察结果一致,NLRP3 缺失显著减轻了 I/R 诱导的肾脏损伤和炎性小体激活标志物。然后,我们观察到线粒体功能障碍,表现为超微结构改变和细胞色素 C(Cyt c)重分布。线粒体靶向抗氧化剂 MitoTEMPO 可防止 mROS 产生过多和线粒体膜电位(MMP)下降。MitoTEMPO 处理还抑制了模拟缺血/再灌注(SI/R)损伤后 NLRP3 炎性小体的激活和 NLRP3 与 TXNIP 的共定位。最后,我们用 TXNIP siRNA 转染 HK-2 细胞,以探讨 TXNIP 在 mROS 诱导的 NLRP3 炎性小体激活中的作用。我们发现 TXNIP siRNA 显著抑制了 NLRP3 炎性小体的激活。这些结果表明,NLRP3 炎性小体通过 mROS-TXNIP-NLRP3 途径激活,并为缺血性 AKI 提供了一个潜在的治疗靶点。
Int J Biochem Cell Biol. 2018-3-21
Zhonghua Yi Xue Za Zhi. 2020-12-29
Front Immunol. 2018-11-12
Front Pharmacol. 2025-6-27
Physiol Rep. 2025-4
Signal Transduct Target Ther. 2024-1-5
Front Med (Lausanne). 2023-11-8
Kidney Dis (Basel). 2023-4-4